Prodrugs pp 1163-1171 | Cite as

Case Study: Amifostine: (Ethyol®)

  • Roger A. Rajewski
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


Amifostine is a prodrug of its free thiol, active metabolite, WR-1065. The thiophosphate promoiety protects the free thiol group of WR-1065 from oxidation to the symmetrical disulfide, WR-33278, while providing a handle for high levels of WR-1065 production at the target tissue. The thiophosphate promoiety of amifostine is cleaved by alkaline phosphatase to produce WR-1065, which accumulates in non-cancerous tissues to a greater extent than in cancerous tissues (Capizzi, 1996).


Radiat Oncol Biol Phys Product Insert Mixed Disulphide Thiophosphoric Acid Radiation Oncology Biol Phys 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bonner HS and Shaw LM. New Dosing Regimens for Amifostine: A Pilot Study to Compare the Relative Bioavailability of Oral and Subcutaneous Administration with Intravenous Infusion. J Clin Pharmacol 2002; 42:166–174PubMedCrossRefGoogle Scholar
  2. Butler JD, Gahl WA, and Tietze F. Cystine Depletion by WR-1065 in Cystinotic Cells. Mechanism of Action. Biochem Pharmacol 1985; 34:2179–2185PubMedCrossRefGoogle Scholar
  3. Calabro-Jones PM, Fahey RC, Smoluk GD, and Ward JF. Alkaline Phosphatase Promotes Radioprotection and Accumulation of WR-15 in V79-171 Cells Incubated in Medium Containing Amifostine. Int J Radiat Oncol Biol Phys 1985; 47:23–27Google Scholar
  4. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, and Fahey RC. Uptake of WR-2721 Derivatives by Cells in Culture: Identification of the Transported Form of the Drug. Cancer Res 1988; 48:3634–3640PubMedGoogle Scholar
  5. Capizzi RL. The Preclinical Basis for Broad-Spectrum Selective Cytoprotection of Normal Tissues from Cytotoxic Therapies by Amifostine (Ethyol). Eur J Cancer 1996; 32A(Suppl 4):S5–16PubMedCrossRefGoogle Scholar
  6. Cassatt DR, Fazenbaker CA, Kifle G, and Bachy CM. Preclinical Studies on the Radioprotective Efficacy and Pharmacokinetics of Subcutaneously Administered Amifostine. Semin Oncol 2002; 29(6 Suppl. 19):2–8PubMedCrossRefGoogle Scholar
  7. Cassatt DR, Fazenbaker CA, Kifle G, and Bachy CM. Subcutaneous Administration of Amifostine (Ethyol) is Equivalent to Intravenous Administration in a Rat Mucositis Model. Int J Radiation Oncology Biol Phys 2003; 57:794–802Google Scholar
  8. Davidson DE, Grenan MM, and Sweeney TR. Biological Characterization of Some Improved Radioprotectors, In: Brady L. Radiation Sensitizers. Their Use in the Clinical Management of Cancer. New York, NY: Masson; 1980:309–320Google Scholar
  9. Ethyol® Product Insert. MedImmune Oncology, Inc.; Ethyol®-Amifostine for Injection product insert N-LB2022 PIGoogle Scholar
  10. Foster-Nora JA and Siden R. Amifostine for Protection from Antineoplastic Drug Toxicity. Am J Health-Syst Pharm 1997; 54:787–800PubMedGoogle Scholar
  11. Gonzalez San Segundo C and Calvo Manuel FA. Radioprotectors. Revista de Oncologia 2002; 4:277–283Google Scholar
  12. Grdina DJ, Nagy D, and Sigdestad CP. Radioprotectors in Treatment Therapy to Reduce Risk in Secondary Tumor Induction. Pharmacol Ther 1988; 39:21–25PubMedCrossRefGoogle Scholar
  13. Kennedy PE, Rajewski RA, and Baldoni JM. Crystalline Amifostine Compositions and Methods of the Preparation and Use of Same. US Patent #5,424,471 (June 13) 1995Google Scholar
  14. Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, Retalis G, and Georgoulias V. Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study. J Clin Oncol 2000; 18:2226–2233PubMedGoogle Scholar
  15. McCulloch W, Scheffler BJ, and Schein PS. New Protective Agents for Bone Morrow in Cancer Therapy. Cancer Invest 1991; 9:279–287PubMedCrossRefGoogle Scholar
  16. Piper JR and Johnston TP. S-ω-(ω-Aminoalkylamino)alkyl Dihydrogen Phosphorthioates. US Patent #3,892,824 (July 1) 1968Google Scholar
  17. Rasey JS, Spence AM, Badger CC, Krohn KA, Vera DM, and Livesey JC. Specific Protection of Different Normal Tissues. Pharmacol Ther 1988; 39:33–43PubMedCrossRefGoogle Scholar
  18. Risley JM, Van Etten RL, Shaw LM, and Bonner H. Hydrolysis of S-2-(3-Aminopropylamino)-ethylphosphorothioate (WR-2721). Biochem Pharmacol 1986; 35:1453–1458PubMedCrossRefGoogle Scholar
  19. Ritter MA, Brown DQ, Glover DJ, and Yuhas JM. In Vitro Studies on the Absorption of Amifostine by Tumors and Normal Tissues. Int J Radiat Oncol Biol Phys 1982; 8:523–526PubMedGoogle Scholar
  20. Romanul F and Bannister RG. Localized Areas of High Alkaline Phosphatase Activity in Endothelial Arteries. Nature 1962; 195:611–612PubMedCrossRefGoogle Scholar
  21. Shaw LM, Turrisi AT, Glover DJ, Bonner HS, Norfleet AL, Weiler C, and Kligerman MM. Human Pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 1986; 12:1501–1504PubMedGoogle Scholar
  22. Shaw LM, Glover D, Turrisi A, Brown DQ, Bonner HS, Norfleet AL, Weiler C, Glick JH, and Kligerman MM. Pharmacokinetics of WR-2721. Pharmacol Ther 1988; 39:195–201PubMedCrossRefGoogle Scholar
  23. Shaw LM, Bonner HS, and Brown DQ. Metabolic Pathways of WR-2721 (Ethyol, Amifostine) in BALB/c Mouse. Drug Metab Dispos 1994; 22:895–902PubMedGoogle Scholar
  24. Shaw LM, Bonner HS, Schucter L, Schiller JH, Nakashima H, and Lieberman R. Amifostine Pharmacokinetics in Cancer Patients: Development of a Population Model. Ther Drug Monit 1997; 19:600CrossRefGoogle Scholar
  25. Shaw LM, Bonner HS, Schucter L, Schiller J, and Lieberman L. Pharmacokinetics of Amifostine: Effects of Dose and Method of Administration. Semin Oncol 1999; 26(2 Suppl. 7):34–36PubMedGoogle Scholar
  26. Shigematsu N, Shwartz J, and Grdina DJ. Protection Against Radiation-Induced Mutagenesis at the HRPT Locus by Spermine and N,N″-(dithiodi-2,1-ethandiyl)bis-1,3-propanediamine (WR-33278). Mutagenesis 1994; 9:355–360PubMedCrossRefGoogle Scholar
  27. Spencer CM and Goa KL. Amifostine: A Review of its Pharmacodynamic and Pharmaco-kinetic Properties, and Therapeutic Potential as a Radioprotector and Cytotoxic Chemoprotector. Drugs 1995; 50:1001–1031PubMedCrossRefGoogle Scholar
  28. Tanaka Y. Clinical Experiences with Chemical Radioprotector in Tumor Radiotherapy: Amifostine. In: Sugahara T. Modification of Radiosensitivity in Cancer Treatment. New York, NY: Academic Press; 1984:61–81Google Scholar
  29. Treskes M and van der Vijgh WJF. WR 2721 as a Modulator of Cisplatin-and Carboplatin-Induced Side Effects in Comparison with other Chemoprotective Agents: a Molecular Approach. Cancer Chemother Pharmacol 1993; 33:93–106PubMedCrossRefGoogle Scholar
  30. Treskes M, Nijtmas LG, Fichtinger-Schepman A, and van der Vijgh WJ. Effects on the Modulating Agent WR2721 and its Main Metabolites on the Formation and Stability of Cisplatin-DNA Adducts In Vitro in Comparison to the Effects of Thiosulphate and Diethyldithiocarbamate. Biochem Pharmacol 1992; 5:1013–1019CrossRefGoogle Scholar
  31. Turrisi AT, Glover DJ, Hurwitz S et. al. Final Report on the Phase I Trial of Single-Dose WR-2721 [S-2-(3-aminopropylamino)-ethylphosphorothiotic acid]. Cancer Treat Rep 1986; 70:1389–1393PubMedGoogle Scholar
  32. Van der Vijgh WJF and Peters GJ. Protection of Normal Tissues from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine (Ethyol): Preclinical Aspects. Semin Oncol 1994; 5:2–7Google Scholar
  33. Yuhas JM. Active Versus Passive Absorption Kinetics as the Basis for Selective Protection of Normal Tissues by S-2-(3-Aminopropylamino)-ethylphosphorothioic Acid. Cancer Res 1980; 40:1519–1524PubMedGoogle Scholar
  34. Yuhas JM, Davis ME, Glover D, Brown DQ, and Ritter M. Circumvention of the Tumor Membrane Barrier to Amifostine Absorption by Reduction of Drug Hydrophilicity. Int J Radiat Oncol Biol Phys 1982; 8:519–522PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Roger A. Rajewski
    • 1
  1. 1.Center for Drug Delivery ResearchThe University of KansasLawrenceUSA

Personalised recommendations